Anti-Angiogenic Properties of Ginsenoside Rg3

Maryam Nakhjavani; Eric Smith; Amanda R. Townsend; Timothy J. Price; Jennifer E. Hardingham

doi:10.3390/molecules25214905

Molecules (Oct 2020)

Anti-Angiogenic Properties of Ginsenoside Rg3

Maryam Nakhjavani,
Eric Smith,
Amanda R. Townsend,
Timothy J. Price,
Jennifer E. Hardingham

Affiliations

Maryam Nakhjavani: Molecular Oncology, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia
Eric Smith: Molecular Oncology, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia
Amanda R. Townsend: Adelaide Medical School, University of Adelaide, Adelaide, SA 5005, Australia
Timothy J. Price: Adelaide Medical School, University of Adelaide, Adelaide, SA 5005, Australia
Jennifer E. Hardingham: Molecular Oncology, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia

DOI: https://doi.org/10.3390/molecules25214905
Journal volume & issue: Vol. 25, no. 21
p. 4905

Abstract

Read online

Ginsenoside Rg3 (Rg3) is a member of the ginsenoside family of chemicals extracted from Panax ginseng. Like other ginsenosides, Rg3 has two epimers: 20(S)-ginsenoside Rg3 (SRg3) and 20(R)-ginsenoside Rg3 (RRg3). Rg3 is an intriguing molecule due to its anti-cancer properties. One facet of the anti-cancer properties of Rg3 is the anti-angiogenic action. This review describes the controversies on the effects and effective dose range of Rg3, summarizes the evidence on the efficacy of Rg3 on angiogenesis, and raises the possibility that Rg3 is a prodrug.

Published in Molecules

ISSN: 1420-3049 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Chemistry: Organic chemistry
Website: http://www.mdpi.com/journal/molecules

About the journal

Abstract

Keywords